Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial.

Ishola, David; Manno, Daniela; Afolabi, Muhammed O; Keshinro, Babajide; Bockstal, Viki; Rogers, Baimba; Owusu-Kyei, Kwabena; Serry-Bangura, Alimamy; Swaray, Ibrahim; Lowe, Brett; +25 more... Kowuor, Dickens; Baiden, Frank; Mooney, Thomas; Smout, Elizabeth; Köhn, Brian; Otieno, Godfrey T; Jusu, Morrison; Foster, Julie; Samai, Mohamed; Deen, Gibrilla Fadlu; Larson, Heidi; Lees, Shelley; Goldstein, Neil; Gallagher, Katherine E; Gaddah, Auguste; Heerwegh, Dirk; Callendret, Benoit; Luhn, Kerstin; Robinson, Cynthia; Leyssen, Maarten; Greenwood, Brian; Douoguih, Macaya; Leigh, Bailah; Watson-Jones, Deborah; EBL3001 study group; (2021) Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial. Lancet Infectious Diseases, 22 (1). pp. 97-109. ISSN 1473-3099 DOI: https://doi.org/10.1016/S1473-3099(21)00125-0

Permanent Identifier

Use this Digital Object Identifier when citing or linking to this resource.

https://doi.org/10.1016/S1473-3099(21)00125-0

Abstract

Share

Downloads

Filename: EBL3001 Adult Manuscript_Final accepted version_LID 2021.pdf

Licence: Creative Commons: Attribution-Noncommercial-No Derivative Works 3.0

Download
[img]

Filename: Supplemental-material.pdf

Licence: Creative Commons: Attribution-Noncommercial-No Derivative Works 4.0

Download
[img]

Downloads

View details

Metrics & Citations


Google Scholar